Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Borja

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Opinion in Cardiology|December 6, 2002
Role of low-molecular-weight heparin in the management of acute coronary syndromesJavier Borja
European Heart Journal|August 27, 2005
Ezetimibe coadministered with fenofibrate: some safety questionsJavier Borja
JAMA|February 17, 2005
Oral antiplatelet therapyJavier Borja
Medicina Clinica|October 3, 2002
[Aldosterone antagonists in the treatment of heart failure]Josep Guindo, Javier Borja
BMJ (Clinical Research Ed.)|June 26, 2004
Amoxicillin for non-severe pneumonia in young children: admission to hospital may indicate adverse effectsJavier Borja, David Rigau
Thrombosis and Haemostasis|March 28, 2002
Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevationJavier Borja, Pere Olivella
Stroke|May 7, 2011
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association"Javier Borja, Julián García-Rafanell
BMJ (Clinical Research Ed.)|July 11, 2006
Hypertrophic cardiomyopathy. Combination of beta blockers and verapamil may be riskyJavier Borja, Iñaki Izquierdo, Josep Guindo
BMJ (Clinical Research Ed.)|December 14, 2004
Seriousness of adverse events: medical judgment is importantJavier Borja, Esther Donado, Mario Souto
Expert Opinion on Drug Safety|June 16, 2006
Antithrombotic treatment in atrial fibrillation. Response to: Bereznicki LR, Peterson GM, Jackson SL, Jeffrey EC: the risks of warfarin use in the elderly. Expert Opin. Drug Saf. (2006) 5(3):417-431Javier Borja, Olga García, Iñaki Izquierdo
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Opinion in Cardiology|December 6, 2002
Role of low-molecular-weight heparin in the management of acute coronary syndromesJavier Borja
European Heart Journal|August 27, 2005
Ezetimibe coadministered with fenofibrate: some safety questionsJavier Borja
JAMA|February 17, 2005
Oral antiplatelet therapyJavier Borja
Medicina Clinica|October 3, 2002
[Aldosterone antagonists in the treatment of heart failure]Josep Guindo, Javier Borja
BMJ (Clinical Research Ed.)|June 26, 2004
Amoxicillin for non-severe pneumonia in young children: admission to hospital may indicate adverse effectsJavier Borja, David Rigau
Thrombosis and Haemostasis|March 28, 2002
Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevationJavier Borja, Pere Olivella
Stroke|May 7, 2011
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association"Javier Borja, Julián García-Rafanell
BMJ (Clinical Research Ed.)|July 11, 2006
Hypertrophic cardiomyopathy. Combination of beta blockers and verapamil may be riskyJavier Borja, Iñaki Izquierdo, Josep Guindo
BMJ (Clinical Research Ed.)|December 14, 2004
Seriousness of adverse events: medical judgment is importantJavier Borja, Esther Donado, Mario Souto
Expert Opinion on Drug Safety|June 16, 2006
Antithrombotic treatment in atrial fibrillation. Response to: Bereznicki LR, Peterson GM, Jackson SL, Jeffrey EC: the risks of warfarin use in the elderly. Expert Opin. Drug Saf. (2006) 5(3):417-431Javier Borja, Olga García, Iñaki Izquierdo
Pageof 3